CompoAtlas

Chronobiane Protect LD 1,9 mg

Food supplement declared in France, decision dated 23 April 2025

Chronobiane Protect LD 1,9 mg is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
not provided
Food business operator placing the product on the market
PILEJE
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Comprimé
Daily dose
1 comprimé à avaler avec une verre d'eau
Directions for use
1 comprimé à avaler avec une verre d'eau au moment du coucher
Intended populations
Population générale, Hommes et femmes de 18 ans et plus
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Femmes enceintes
Objectives stated by the manufacturer (these are not authorised claims)
Sommeil

Declaration 260467, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

None of the rules we check applies to the declared ingredients.

Declared composition

Plants

PlantPartPreparationPer day
Adansonia digitata L.Fruit (pulpe)Poudre (de plantes séchées ou broyées)305 mg
Melissa officinalis L.Parties aériennesPoudre (de plantes séchées ou broyées)150 mg
Melissa officinalis L.Parties aériennesExtrait sec aqueux50 mg
Bambusa bambos (L.) VossExsudatPoudre (de plantes séchées ou broyées)40 mg

Substances

NamePer day
mélatonine1.9 mg

Other active ingredients

NamePer day
Hydrolysat enzymatique de protéines de riznot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Sulfate de zincZinc25 mg15 mg

Additives

E470b, E401, E460, E341

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Réservé aux adultes. Déconseillé aux femmes enceintes et/ou allaitantes, aux personnes souffrant de maladies inflammatoires ou auto-immunes, aux épileptiques, aux asthmatiques et aux personnes souffrant de troubles de l’humeur, du comportement ou de la personnalité. Ne pas dépasser la dose journalière recommandée. Risque de somnolence. En cas d’association avec un traitement médicamenteux, demandez conseil à votre médecin ou pharmacien.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Melissa officinalis L.
    Read the warning, when it applies and the studies cited

    LEMON BALM -MELISSA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 April 2024

  • mélatonine
    Read the warning, when it applies and the studies cited

    MELATONIN - Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications for seizure, blood pressure, to suppress the immune system, to affect mental state or increase sedation, steroids or blood thinners (Wirtz et al. 2008; IOM 2004; Herxheimer and Petrie 2002; Lusardi et al. 2000; Maestroni 1993).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have cardiovascular, immune, liver or kidney disease, seizure disorder, asthma or diabetes (Peschke and Mühlbauer 2010; Carrillo-Vico et al. 2005; IOM 2004; der Marderosian and Beuttlers 2003; Sutherland et al. 2003; Calvo et al. 2002; Herxheimer and Petrie 2002; Sutherland et al. 2002; Cagnacci et al. 2001a; Arangino et al. 1999; Sheldon 1998; Maestroni 1993).

    12 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid taking with alcohol or products that cause drowsiness (Herxheimer and Petrie 2002; Holliman and Chyka 1997).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid driving or using machinery for 5 hours (Avery et al. 1998; Suhner et al. 1998b).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Buscemi et al. 2004; IOM 2004; Dipiro et al. 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (IOM 2004).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if allergy occurs or if you experience headache, confusion, or nausea (Herxheimer and Petrie 2002).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

    MELATONIN - Sublingual

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications for seizure, blood pressure, to suppress the immune system, to affect mental state or increase sedation, steroids or blood thinners (Wirtz et al. 2008; IOM 2004; Herxheimer and Petrie 2002; Lusardi et al. 2000; Maestroni 1993).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a cardiovascular, immune, liver or kidney disease, seizure disorder, asthma or diabetes (Peschke and Mühlbauer 2010; Carrillo-Vico et al. 2005; IOM 2004; der Marderosian and Beuttlers 2003; Sutherland et al. 2003; Calvo et al. 2002; Herxheimer and Petrie 2002; Sutherland et al. 2002; Cagnacci et al. 2001a; Arangino et al. 1999; Sheldon 1998; Maestroni 1993).

    12 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid taking with alcohol or products that cause drowsiness (Herxheimer and Petrie 2002; Holliman and Chyka 1997).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid driving or using machinery for 5 hours (Avery et al. 1998; Suhner et al. 1998b).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Buscemi et al. 2004; IOM 2004; Dipiro et al. 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (IOM 2004).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if allergy occurs or if you experience headache, confusion, or nausea (Herxheimer and Petrie 2002).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line